Dapivirine Ring: Phase III Results

Overview of results: Two large clinical trials — The Ring Study and ASPIRE — showed that IPM's monthly vaginal ring containing the antiretroviral drug dapivirine can help reduce women's HIV-1 risk by approximately 30 percent overall and is safe for long-term use. Notably, greater HIV risk reduction was associated with increased ring use — participants who used the ring at least some of the time saw their HIV infection risk cut by 45 percent across both studies.

Next steps for the ring: This is the first time a microbicide to prevent HIV has confirmed statistically significant efficacy across two Phase III studies. As the first long-acting HIV prevention method, the dapivirine ring could be an important new self-initiated option for women, who bear the greatest burden of the global HIV/AIDS epidemic. IPM, the ring's developer and regulatory sponsor, is pursuing approvals from global and national regulatory authorities to license the product in countries where women face the highest risk. Two open-label extension studies, DREAM and HOPE, are now underway to provide the ring to former Ring Study and ASPIRE participants, respectively, and to help determine how the ring could fit into women’s lives. 

Learn more about the results from the Phase III dapivirine ring studies: